Supernus Pharmaceuticals Inc. shares fell 23.4 percent Tuesday after the company dropped one of two doses of an experimental treatment for impulsive aggression in children with attention deficit hyperactivity disorder (ADHD) that it was evaluating in twin phase III studies.